Does the media refer more to FATE or GANX?

In the previous week, Fate Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 10 mentions for Fate Therapeutics and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat Fate Therapeutics' score of 0.48 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SABS or GANX more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Gain Therapeutics N/A -161.59% -118.36%

Does the media favor SABS or GANX?

In the previous week, SAB Biotherapeutics had 12 more articles in the media than Gain Therapeutics. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat SAB Biotherapeutics' score of 0.33 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MYGN or GANX?

In the previous week, Gain Therapeutics had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Gain Therapeutics and 8 mentions for Myriad Genetics. Gain Therapeutics' average media sentiment score of 1.01 beat Myriad Genetics' score of 0.54 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GANX or FULC more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Fulcrum Therapeutics N/A -25.38% -24.15%

Does the media prefer GANX or FULC?

In the previous week, Gain Therapeutics had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 9 mentions for Gain Therapeutics and 5 mentions for Fulcrum Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat Fulcrum Therapeutics' score of 0.66 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRDA or GANX?

In the previous week, Entrada Therapeutics had 12 more articles in the media than Gain Therapeutics. MarketBeat recorded 21 mentions for Entrada Therapeutics and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat Entrada Therapeutics' score of 0.21 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gain Therapeutics (GANX) Competitors

$2.12 -0.04 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$2.14 +0.02 (+0.94%)

As of 07:38 PM Eastern

Compare

GANX vs. FATE, SABS, MYGN, FULC, and TRDA

Should you buy Gain Therapeutics stock or one of its competitors? Gain Therapeutics's main competitors and comparable companies include Fate Therapeutics (FATE), SAB Biotherapeutics (SABS), Myriad Genetics (MYGN), Fulcrum Therapeutics (FULC), and Entrada Therapeutics (TRDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gain Therapeutics compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Fate Therapeutics currently has a consensus target price of $5.90, suggesting a potential upside of 129.57%. Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 253.77%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Gain Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	45.05	-$136.32M	-$1.09	N/A
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A

Gain Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -60.87% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-60.87%	-39.89%
Gain Therapeutics	N/A	-161.59%	-118.36%

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Fate Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 10 mentions for Fate Therapeutics and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat Fate Therapeutics' score of 0.48 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fate Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Summary

Fate Therapeutics and Gain Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

SAB Biotherapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

SAB Biotherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 224.32%. Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 253.77%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

SAB Biotherapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	255.05	$13.27M	-$1.30	N/A
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A

SAB Biotherapeutics' return on equity of -6.74% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Gain Therapeutics	N/A	-161.59%	-118.36%

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, SAB Biotherapeutics had 12 more articles in the media than Gain Therapeutics. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat SAB Biotherapeutics' score of 0.33 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SAB Biotherapeutics beats Gain Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Gain Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.35	-$365.90M	-$1.19	N/A
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A

Myriad Genetics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Gain Therapeutics	N/A	-161.59%	-118.36%

Myriad Genetics presently has a consensus target price of $5.38, suggesting a potential upside of 77.39%. Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 253.77%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Gain Therapeutics had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Gain Therapeutics and 8 mentions for Myriad Genetics. Gain Therapeutics' average media sentiment score of 1.01 beat Myriad Genetics' score of 0.54 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Gain Therapeutics beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to Fulcrum Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Gain Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 253.77%. Fulcrum Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 119.25%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Gain Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market.

Fulcrum Therapeutics' return on equity of -25.38% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

In the previous week, Gain Therapeutics had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 9 mentions for Gain Therapeutics and 5 mentions for Fulcrum Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat Fulcrum Therapeutics' score of 0.66 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Gain Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A
Fulcrum Therapeutics	$80M	3.57	-$74.88M	-$1.21	N/A

Summary

Gain Therapeutics beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Entrada Therapeutics had 12 more articles in the media than Gain Therapeutics. MarketBeat recorded 21 mentions for Entrada Therapeutics and 9 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.01 beat Entrada Therapeutics' score of 0.21 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Gain Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Gain Therapeutics	N/A	-161.59%	-118.36%

Gain Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	11.43	-$143.75M	-$3.96	N/A
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A

Entrada Therapeutics presently has a consensus price target of $17.75, suggesting a potential upside of 137.94%. Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 253.77%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Entrada Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

Gain Therapeutics beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.49M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-4.24	6.29	211.09	21.74
Price / Sales	1,850.34	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	8.15	16.78	12.91	6.24
Net Income	-$20.16M	-$13.32M	$3.45B	$347.60M
7 Day Performance	16.48%	1.74%	1.12%	1.07%
1 Month Performance	26.19%	1.60%	1.79%	1.03%
1 Year Performance	37.66%	56.43%	67.69%	20.77%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	2.8247 of 5 stars	$2.12 -1.9%	$7.50 +253.8%	+39.4%	$94.49M	$50K	N/A	20	Earnings Report Analyst Forecast
FATE Fate Therapeutics	3.1324 of 5 stars	$2.57 +2.8%	$5.13 +99.4%	+123.0%	$291.40M	$6.65M	N/A	550	News Coverage Earnings Report Analyst Forecast Gap Up High Trading Volume
SABS SAB Biotherapeutics	2.6876 of 5 stars	$3.85 +1.6%	$12.00 +211.7%	+74.4%	$289.80M	$1.32M	N/A	140	Positive News High Trading Volume
MYGN Myriad Genetics	3.4003 of 5 stars	$3.17 +5.0%	$5.38 +69.6%	-46.0%	$288.86M	$824.50M	N/A	2,700
FULC Fulcrum Therapeutics	3.4046 of 5 stars	$3.80 +2.4%	$8.20 +115.8%	-45.8%	$283.06M	$80M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. FATE, SABS, MYGN, FULC, and TRDA

How does Gain Therapeutics compare to Fate Therapeutics?

Summary

How does Gain Therapeutics compare to SAB Biotherapeutics?

Summary

How does Gain Therapeutics compare to Myriad Genetics?

Summary

How does Gain Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Gain Therapeutics compare to Entrada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. FATE, SABS, MYGN, FULC, and TRDA

How does Gain Therapeutics compare to Fate Therapeutics?

Do analysts prefer FATE or GANX?

Which has stronger earnings & valuation, FATE or GANX?

Is FATE or GANX more profitable?

Do institutionals & insiders hold more shares of FATE or GANX?

Does the media refer more to FATE or GANX?

Which has more volatility and risk, FATE or GANX?

Summary

How does Gain Therapeutics compare to SAB Biotherapeutics?

Which has more volatility and risk, SABS or GANX?

Do analysts recommend SABS or GANX?

Which has stronger valuation and earnings, SABS or GANX?

Is SABS or GANX more profitable?

Do institutionals and insiders hold more shares of SABS or GANX?

Does the media favor SABS or GANX?

Summary

How does Gain Therapeutics compare to Myriad Genetics?

Which has stronger earnings and valuation, MYGN or GANX?

Which has more risk and volatility, MYGN or GANX?

Is MYGN or GANX more profitable?

Do analysts prefer MYGN or GANX?

Does the media favor MYGN or GANX?

Do insiders and institutionals hold more shares of MYGN or GANX?

Summary

How does Gain Therapeutics compare to Fulcrum Therapeutics?

Do analysts recommend GANX or FULC?

Which has more volatility & risk, GANX or FULC?

Is GANX or FULC more profitable?

Does the media prefer GANX or FULC?

Do institutionals & insiders believe in GANX or FULC?

Which has stronger earnings and valuation, GANX or FULC?

Summary

How does Gain Therapeutics compare to Entrada Therapeutics?

Does the media prefer TRDA or GANX?

Do institutionals and insiders hold more shares of TRDA or GANX?

Is TRDA or GANX more profitable?

Which has better valuation & earnings, TRDA or GANX?

Do analysts rate TRDA or GANX?

Which has more volatility & risk, TRDA or GANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools